Patents Assigned to MAP Pharmaceuticals, Inc.
-
Patent number: 10172853Abstract: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.Type: GrantFiled: March 28, 2017Date of Patent: January 8, 2019Assignee: MAP PHARMACEUTICALS, INC.Inventors: Robert O. Cook, Stephen B. Shrewsbury, Nabih N. Ramadan, Thomas A. Armer
-
Patent number: 9833451Abstract: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.Type: GrantFiled: October 23, 2015Date of Patent: December 5, 2017Assignee: MAP Pharmaceuticals, Inc.Inventors: Robert O. Cook, Stephen B. Shrewsbury, Nabih N. Ramadan, Thomas A. Armer
-
Patent number: 9610415Abstract: The present invention provides for an enhanced eductor element that significantly increases the amount of pressure generated at the siphon tube without significantly increasing the flow resistance through the eductor. The invention further provides for breath-actuated inhalation devices including the enhanced eductor element as an actuation mechanism.Type: GrantFiled: November 18, 2015Date of Patent: April 4, 2017Assignee: MAP Pharmaceuticals, Inc.Inventors: Benjamin Stedman, Prashant Kakade, Darrell Woehler, John Leonard
-
Patent number: 9480803Abstract: A medicament dispenser, in particular a metered dose inhaler, which is able to count the number of time the dispenser is activated and then disable the device, which then prevents any additional medicament from being dispensed. Additional embodiments include a medicament dispenser which are adapted to display either the number of activations that have occurred or the number of activations remaining.Type: GrantFiled: January 15, 2014Date of Patent: November 1, 2016Assignee: MAP Pharmaceuticals, Inc.Inventor: Alfred Sugianto
-
Patent number: 9394314Abstract: 8?-Hydroxy-Dihydroergotamine (8?-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of migraine disorders using the compounds, compositions, dosage forms and administration techniques disclosed herein.Type: GrantFiled: December 19, 2013Date of Patent: July 19, 2016Assignee: MAP Pharmaceuticals, Inc.Inventors: Donald J. Kellerman, Thomas Armer, Jian Zhang
-
Patent number: 9365591Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: August 28, 2015Date of Patent: June 14, 2016Assignee: MAP Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Patent number: 9227030Abstract: The present invention provides for an enhanced eductor element that significantly increases the amount of pressure generated at the siphon tube without significantly increasing the flow resistance through the eductor. The invention further provides for breath-actuated inhalation devices comprising the enhanced eductor element as an actuation mechanism.Type: GrantFiled: December 23, 2010Date of Patent: January 5, 2016Assignee: MAP Pharmaceuticals, Inc.Inventors: Benjamin Stedman, Prashant Kakade, Darrell Woehler, John Leonard
-
Patent number: 9216259Abstract: A pulmonary drug delivery device having one or more vortexing elements which impart beneficial flow characteristics to an inspiratory air flow carrying a medicament into the patient's lungs.Type: GrantFiled: July 26, 2013Date of Patent: December 22, 2015Assignee: MAP Pharmaceuticals, Inc.Inventor: Prashant Kakade
-
Patent number: 9161912Abstract: An inhalation device for administering one or more sedatives via pulmonary inhalation for treating a sleep disturbance.Type: GrantFiled: September 12, 2013Date of Patent: October 20, 2015Assignee: MAP Pharmaceuticals, Inc.Inventors: Robert Owen Cook, Thomas Armer
-
Patent number: 9150593Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: December 12, 2014Date of Patent: October 6, 2015Assignee: MAP Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Patent number: 9012640Abstract: Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B receptor and 5-HT2C receptors the using the compounds and compositions disclosed herein.Type: GrantFiled: June 22, 2012Date of Patent: April 21, 2015Assignee: MAP Pharmaceuticals, Inc.Inventors: Jian Zhang, Thomas A. Armer
-
Patent number: 8969374Abstract: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: October 3, 2013Date of Patent: March 3, 2015Assignee: MAP Pharmaceuticals, Inc.Inventors: Jian Zhang, Robert O. Cook
-
Patent number: 8946420Abstract: Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein. In other embodiments, provided herein are methods of agonizing dopaminergic D2 receptors and/or antagonizing or inhibiting activity of receptors such as the 5-HT2 receptors using the compounds and compositions disclosed herein.Type: GrantFiled: June 22, 2012Date of Patent: February 3, 2015Assignee: Map Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Patent number: 8933093Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: October 7, 2013Date of Patent: January 13, 2015Assignee: Map Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Patent number: 8895743Abstract: Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such as, for example, are methods for antagonizing the 5-HT2B receptor without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein such as, for example, are methods of agonizing the 5-HT1A receptor using the compounds and compositions disclosed herein.Type: GrantFiled: December 19, 2013Date of Patent: November 25, 2014Assignee: Map Pharmaceuticals, Inc.Inventors: Libo Wu, Jian Zhang
-
Patent number: 8841448Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: October 7, 2013Date of Patent: September 23, 2014Assignee: Map Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Publication number: 20140194434Abstract: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicant: MAP Pharmaceuticals, Inc.Inventors: Robert O. Cook, THOMAS A. ARMER, Sergey Alexandrovich KOSAREV, Dejian Xie, Jian Zhang
-
Publication number: 20140194435Abstract: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicant: MAP Pharmaceuticals, Inc.Inventors: Robert O. COOK, Thomas A. ARMER, Sergey Alexandrovich KOSAREV, Dejian XIE, Jian ZHANG
-
Publication number: 20140179707Abstract: Provided herein are 8?-Hydroxy-2-CF3-dihydroergotamine (8?OH-2-CF3-DHE) compounds, compositions, and dosage forms containing such compositions. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Patent number: 8720433Abstract: A medicament dispenser, in particular a metered dose inhaler, which is able to count the number of time the dispenser is activated and then disable the device, which then prevents any additional medicament from being dispensed. Additional embodiments include a medicament dispenser which are adapted to display either the number of activations that have occurred or the number of activations remaining.Type: GrantFiled: May 7, 2009Date of Patent: May 13, 2014Assignee: Map Pharmaceuticals, Inc.Inventor: Alfred Sugianto